| Wisdo Family Medicine, James John Wisdo Do Pa | |
|
2685 Sw 32nd Pl Ste 500 Ocala FL 34471-7867 | |
| (352) 622-9007 | |
| (352) 622-2179 |
| Full Name | Wisdo Family Medicine, James John Wisdo Do Pa |
|---|---|
| Speciality | Family Medicine |
| Location | 2685 Sw 32nd Pl Ste 500, Ocala, Florida |
| Authorized Official Name and Position | Janice E Medley (OFFICE MANAGER) |
| Authorized Official Contact | 3526229007 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Wisdo Family Medicine, James John Wisdo Do Pa 2685 Sw 32nd Pl Ste 500 Ocala FL 34471-7867 Ph: (352) 622-9007 | Wisdo Family Medicine, James John Wisdo Do Pa 2685 Sw 32nd Pl Ste 500 Ocala FL 34471-7867 Ph: (352) 622-9007 |
| NPI Number | 1053458455 |
|---|---|
| Provider Enumeration Date | 02/01/2007 |
| Last Update Date | 07/21/2020 |
| Medicare PECOS PAC ID | 1456315282 |
|---|---|
| Medicare Enrollment ID | O20041112000137 |
News Archive
dorsaVi Pty Limited, today introduced ViSafe, a non-invasive, wearable sensor system that measures movement and muscle activity while on the job, enabling companies to redesign certain workplace activities to improve safety and prevent injuries.
Most studies into the impact of technology use on psychological wellbeing rely on flawed measures say researchers.
The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.
Between 8 and 12 million Americans are affected by peripheral arterial disease, or PAD, where the arteries that bring blood to the legs are blocked by atherosclerotic plaque.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053458455 | NPI | - | NPPES |
| 253125900 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Secondary |
| 207Q00000X | Family Medicine | (Florida) | Primary |
| Provider Name | James John Wisdo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1508837998 PECOS PAC ID: 4385605823 Enrollment ID: I20041019000886 |
News Archive
dorsaVi Pty Limited, today introduced ViSafe, a non-invasive, wearable sensor system that measures movement and muscle activity while on the job, enabling companies to redesign certain workplace activities to improve safety and prevent injuries.
Most studies into the impact of technology use on psychological wellbeing rely on flawed measures say researchers.
The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.
Between 8 and 12 million Americans are affected by peripheral arterial disease, or PAD, where the arteries that bring blood to the legs are blocked by atherosclerotic plaque.
› Verified 8 days ago
| Provider Name | Trisha M Kimball |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467900142 PECOS PAC ID: 0244586410 Enrollment ID: I20180629001387 |
News Archive
dorsaVi Pty Limited, today introduced ViSafe, a non-invasive, wearable sensor system that measures movement and muscle activity while on the job, enabling companies to redesign certain workplace activities to improve safety and prevent injuries.
Most studies into the impact of technology use on psychological wellbeing rely on flawed measures say researchers.
The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.
Between 8 and 12 million Americans are affected by peripheral arterial disease, or PAD, where the arteries that bring blood to the legs are blocked by atherosclerotic plaque.
› Verified 8 days ago
News Archive
dorsaVi Pty Limited, today introduced ViSafe, a non-invasive, wearable sensor system that measures movement and muscle activity while on the job, enabling companies to redesign certain workplace activities to improve safety and prevent injuries.
Most studies into the impact of technology use on psychological wellbeing rely on flawed measures say researchers.
The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.
Between 8 and 12 million Americans are affected by peripheral arterial disease, or PAD, where the arteries that bring blood to the legs are blocked by atherosclerotic plaque.
› Verified 8 days ago
Siva Md Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2845 Se 3rd Ct, Ocala, FL 34471 Phone: 352-369-5300 Fax: 352-369-5309 | |
Central Florida Heart Group P.a. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 6600 Sw Hwy 200, Suite 300, Ocala, FL 34476 Phone: 352-237-4116 Fax: 352-237-1785 | |
Munroe Professional Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1511 Sw 1st Ave, Ocala, FL 34471 Phone: 352-867-8311 Fax: 352-867-1053 | |
Integrative Health Care And Physical Medicine Ocala Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3256 S Pine Ave Ste 301, Ocala, FL 34471 Phone: 352-369-6325 Fax: 352-369-6329 | |
Poonam Warman M D P A Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1500 Se Magnolia Ext Ste 202, Ocala, FL 34471 Phone: 352-369-6139 | |
Marion Internal Medicine Associates Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1805 Se Lake Weir Ave, Ocala, FL 34471 Phone: 352-629-9634 Fax: 352-629-6350 | |
Ocala Innovative Medical, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5481 Sw 60th St, Unit 302, Ocala, FL 34474 Phone: 352-840-0444 |